Back to News
Market Impact: 0.1
AIM ImmunoTech Highlights Ampligen's Broad-Spectrum Antiviral Potential
Source: Nasdaq
Healthcare & Biotech
AIM ImmunoTech said Monday it highlighted recent media coverage of Ampligen (rintatolimod), its investigational broad-spectrum antiviral and immunomodulatory therapy. The article provides no additional details on the coverage, clinical results, or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
AIM0.10
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Why is NeoGenomics stock sliding today?
- Up 57% since June: this AI-picked pharma stock keeps climbing
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- Vaxcyte shares surge on late-stage vaccine trial success
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- AI Software for Buy-Side Teams: Build the Research Stack